FEVIPIPRANT

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H17F3N2O4S
Molecular Weight	426.409
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of FEVIPIPRANT

Structure Search

SMILES

CC1=C(CC(O)=O)C2=CC=CN=C2N1CC3=CC=C(C=C3C(F)(F)F)S(C)(=O)=O

InChI

InChIKey=GFPPXZDRVCSVNR-UHFFFAOYSA-N

InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)

HIDE SMILES / InChI

Molecular Formula	C19H17F3N2O4S
Molecular Weight	426.409
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:19:31 UTC 2023` Edited by `admin` on `Sat Dec 16 08:19:31 UTC 2023`
Record UNII	2PEX5N7DQ4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FEVIPIPRANT

Official Name

English

FEVIPIPRANT [USAN]

Common Name

English

2-(1-((4-METHANESULFONYL-2-(TRIFLUOROMETHYL)PHENYL)METHYL(-2-METHYL-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)ACETIC ACID

Common Name

English

QAW039

Code

English

FEVIPIPRANT [JAN]

Common Name

English

NVP-QAW039

Code

English

QAW-039

Code

English

(1-(4-((METHANE)SULFONYL)-2-TRIFLUOROMETHYLBENZYL)-2-METHYL-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)ACETIC ACID

Common Name

English

Fevipiprant [WHO-DD]

Common Name

English

fevipiprant [INN]

Common Name

English

Code System Code Type Description

DRUG BANK

DB12011

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

NCI_THESAURUS

C166588

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

USAN

BC-37

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

CAS

872365-14-5

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

ChEMBL

CHEMBL3137332

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

INN

9682

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

SMS_ID

100000174166

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

FDA UNII

2PEX5N7DQ4

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

WIKIPEDIA

Fevipiprant

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

EPA CompTox

DTXSID501336031

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

PUBCHEM

23582412

Created by admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023

PRIMARY

Related Record Type Details


					0M77ZW789J

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7

METABOLIC ENZYME -> SUBSTRATE

Amount:


					W80H4WI8LW

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B17

METABOLIC ENZYME -> SUBSTRATE

Amount:


					2PEX5N7DQ4

EXCRETED UNCHANGED

Qualification:

URINE

Amount:


					66DDF797LP

OATP-8

TRANSPORTER -> SUBSTRATE

Amount:


					IHQ709299P

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A3

METABOLIC ENZYME -> SUBSTRATE

Amount:


					2PEX5N7DQ4

EXCRETED UNCHANGED

Qualification:

FECAL

Amount:


					ZWJ2Y6JZWY

OAT-3

TRANSPORTER -> SUBSTRATE

Amount:


					X4HG9CCA5A

PROSTAGLANDIN D2 RECEPTOR 2

TARGET -> INHIBITOR

Qualification:

Kd

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE

Amount:

Related Record Type Details


					WMF8QFQ5AF

(2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(2-(2-METHYL-1-((4-METHYLSULFONYL-2-(TRIFLUOROMETHYL)PHENYL)METHYL)PYRROLO(2,3-B)PYRIDIN-3-YL)ACETYL)OXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE INACTIVE -> PARENT

Qualification:

FECAL

Amount:


					WMF8QFQ5AF

(2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(2-(2-METHYL-1-((4-METHYLSULFONYL-2-(TRIFLUOROMETHYL)PHENYL)METHYL)PYRROLO(2,3-B)PYRIDIN-3-YL)ACETYL)OXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

URINE

Amount:


					WMF8QFQ5AF

(2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(2-(2-METHYL-1-((4-METHYLSULFONYL-2-(TRIFLUOROMETHYL)PHENYL)METHYL)PYRROLO(2,3-B)PYRIDIN-3-YL)ACETYL)OXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE INACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA

Amount:

Related Record Type Details


					2PEX5N7DQ4

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC				ORAL ADMINISTRATION SINGLE DOSE

Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION SINGLE DOSE